Finally, we analyzed ZNF224 mRNA expression in peripheral mononuclear cells from 30 adult patients with BCR-ABL positive chronic phase CML (CP-CML) at diagnosis (Dx) and after three months (FU) of treatment with imatinib standard dose as a first-line therapy. This evidence concerns the gene ZNF224 and chronic myelogenous leukemia, BCR-ABL1 positive.